Business Model Breakdown
How Coherus Oncology Inc Makes Money
CHRS
Market Cap
$250M
Annual Revenue
$42M
Profit Margin
-434.2%
The Short Version
Coherus Oncology Inc. is a biopharmaceutical company that develops and commercializes innovative therapies, primarily focusing on oncology. Its current flagship product, LOQTORZI, is a first-in-class drug approved for treating nasopharyngeal carcinoma (NPC), a type of head and neck cancer. Coherus generates revenue by selling LOQTORZI to healthcare providers and also by advancing a pipeline of novel oncology treatments through clinical trials, with the long-term goal of bringing additional proprietary drugs to market to address significant unmet medical needs in cancer care. The business model involves substantial upfront research and development investment with the aim of high-margin product sales upon regulatory approval.
Where the Revenue Comes From
LOQTORZI sales (~96.7% of FY2025 TTM revenue)
Residual biosimilar product sales (post-UDENYCA divestiture, this contribution is expected to be minimal)
Who buys: Oncologists, hospitals, specialized cancer treatment centers, and ultimately, patients suffering from various forms of cancer.
Why It Works (Competitive Advantages)
- ✔First-in-class FDA approved therapy (LOQTORZI) for nasopharyngeal carcinoma (NPC)
- ✔Strong 6-year overall survival data for LOQTORZI (Phase 3 JUPITER-02 trial)
- ✔Strategic focus and capital allocation towards proprietary oncology pipeline
Economic Moat: Narrow (Intangible Assets/IP (FDA approval for LOQTORZI, patents on pipeline drugs))
What Our Analysis Says
DVR Score as of April 9, 2026
Coherus Oncology has demonstrated a significant pivot to proprietary oncology, with LOQTORZI's 2025 revenue more than doubling, affirming its first-in-class opportunity for NPC. Critically, the company has drastically de-risked its financial profile by reducing debt by 90% and securing a substantial cash position via asset divestiture, directly addressing previous concerns about financial precariousness and runway. While still deeply unprofitable with a high cash burn, these strategic financial maneuvers provide a much stronger foundation for pipeline development (with multiple readouts expected in 2026) and commercial execution, enhancing its 10x growth potential despite ongoing high operational risk. **Score Change Explanation:** The previous score of 4.5/10 was driven by high financial risk from tight runway and high cash burn. Since then, the company has materially improved its financial health by reducing debt by ~90% to $38.8M, securing $172.1M in cash, and divesting UDENYCA for up to $558.4M, explicitly to fund the oncology pipeline. LOQTORZI's revenue more than doubled, demonstrating early commercial success. These significant de-risking actions and clear execution on the oncology pivot, alongside advancing the broader pipeline with 2026 catalysts, substantially strengthen the company's long-term viability and growth prospects, justifying a +2.6 point increase to 7.1/10.